Voor zorgverleners

146 for Lipid Management After ACS

Dupixent® CRSwNP

2024 ESC Guidelines for the management of chronic coronary syndromes

Felicita Andreotti, Italy; Christiaan J M Vrints, Belgium

Real-World Insights on Managing Immune-Mediated Thrombotic Thrombocytopenic Purpura with Caplacizumab

Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a rare and life-threatening blood disorder characterized by severe deficiency of the enzyme ADAMTS13, leading to the formation of microthrombi in small blood vessels. This condition requires prompt and effective treatment to prevent serious complications. Caplacizumab is an innovative nanobody^® and cornerstone in the treatment of iTTP.¹ This article delves into real-world data from Belgian hospitals on the use of caplacizumab, highlighting its efficacy, safety, and impact on patient outcomes.²

Infographic: Impact of Type 1 Diabetes Diagnosis

This infographic summarizes survey data^* about the impact that families in the Netherlands and Belgium have felt when being diagnosed with autoimmune Type 1 Diabetes (T1D).

Detectability of Autoimmune Type 1 Diabetes

Systematic early detection of autoimmune Type 1 Diabetes might be a new way to avoid acute and chronic complications of the condition.^1-5 This new approach may play a role as a revolutionary shift, helping to shape the future of Type 1 Diabetes management.²

Time to Rethink T1D?

Start to think differently about Type 1 Diabetes by considering the pre-symptomatic stages of the condition and how it affects people of all ages and their families.

Holland Bio: INZET NIEUWE VACCINS IN NEDERLAND 2.0

Volgens onderzoek van Holland Bio duurt het in Nederland tot nu toe gemiddeld 7-9 jaar na registratie door EMA voor een vaccin wordt opgenomen in het Rijksvaccinatieprogramma (RVP).

Praktijkervaring met Beyfortus® in Galicië

Publicatie Lancet Infectious Diseases (30 april 2024)⁴: "Effectiviteit en impact van universele profylaxe met nirsevimab bij zuigelingen tegen ziekenhuisopname door het respiratoir syncytieel virus in Galicië, Spanje: eerste resultaten van een  populatiegebaseerd longitudinaal onderzoek."